TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from MAIA Biotechnology, Inc. ( (MAIA) ) is now available.
On November 21, 2025, MAIA Biotechnology announced the ongoing progress of its ateganosine clinical program at the SITC 2025 conference. The company highlighted the enrollment of 12 patients in the Phase 2 THIO-101 trial and the commencement of patient screening in the Phase 3 THIO-104 trial for NSCLC. The FDA has granted Fast Track designation for ateganosine, which has shown promising results in extending overall survival in patients resistant to current treatments. The trials are expected to advance the development of ateganosine as a novel therapy for NSCLC, potentially leading to early commercial approval and offering new hope for patients with significant unmet medical needs.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Their lead program involves ateganosine (THIO), a first-in-class cancer telomere targeting agent, aimed at treating non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
Average Trading Volume: 568,027
Technical Sentiment Signal: Sell
Current Market Cap: $34.07M
Learn more about MAIA stock on TipRanks’ Stock Analysis page.